{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:47:27Z","timestamp":1790668047140,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014571","name":"Alvin J. Siteman Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.lungcan.2026.109382","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:12:57Z","timestamp":1774311177000},"page":"109382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evaluating the safety and efficacy of chemotherapy in patients with relapsed small cell lung cancer combined with allopurinol and MycoPhenolate (CLAMP)"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1953-9041","authenticated-orcid":false,"given":"Brendan","family":"Knapp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7069-5456","authenticated-orcid":false,"given":"Saiama N.","family":"Waqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-895X","authenticated-orcid":false,"given":"Jeffrey P.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett H.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Vellequette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksis","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Turlington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Plonsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0287-7362","authenticated-orcid":false,"given":"Ningying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9793-913X","authenticated-orcid":false,"given":"Anjali","family":"Rohatgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramaswamy","family":"Govindan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Devarakonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Morgensztern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109382_b0005","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"IMpower133 Study Group, First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109382_b0010","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"CASPIAN investigators, Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109382_b0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician\u2019s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2026.109382_b0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109382_b0025","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109382_b0030","doi-asserted-by":"crossref","first-page":"15437","DOI":"10.1038\/srep15437","article-title":"Topotecan for relapsed small-cell lung cancer: Systematic review and meta-analysis of 1347 patients","volume":"5","author":"Horita","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2026.109382_b0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000486622","article-title":"A phase II study of irinotecan for patients with previously treated small-cell lung cancer","volume":"94","author":"Kondo","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.lungcan.2026.109382_b0040","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1200\/JCO.1992.10.8.1225","article-title":"CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer","volume":"10","author":"Masuda","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109382_b0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2008.11.002","article-title":"A multicenter randomized phase II study of the irinotecan\/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer","volume":"65","author":"Pallis","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109382_b0050","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109382_b0055","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","article-title":"MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition","volume":"31","author":"Mollaoglu","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2026.109382_b0060","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1038\/s41467-018-06162-9","article-title":"Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer","volume":"9","author":"Wagner","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2026.109382_b0065","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","article-title":"MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate","volume":"38","author":"Ireland","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2026.109382_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2018.06.005","article-title":"Inosine monophosphate dehydrogenase dependence in a subset of small cell lung cancers","author":"Huang","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.lungcan.2026.109382_b0075","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139929","article-title":"Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer","volume":"131","author":"Huang","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lungcan.2026.109382_b0080","doi-asserted-by":"crossref","first-page":"8301","DOI":"10.1158\/1078-0432.CCR-04-0747","article-title":"Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients","volume":"10","author":"Takebe","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109382_b0085","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0065-2571(88)90029-5","article-title":"Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia","volume":"27","author":"Weber","year":"1988","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.lungcan.2026.109382_b0090","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109382_b0095","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/jlts.2001.23356","article-title":"A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients","volume":"7","author":"Wiesner","year":"2001","journal-title":"Liver Transpl."},{"key":"10.1016\/j.lungcan.2026.109382_b0100","unstructured":"U.S.A. Genentech, Mycophenolate Mofetil [Package Insert], (2021). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/050722s049s051,050723s049s051,050758s047s049lbl.pdf (accessed January 13, 2026)."},{"key":"10.1016\/j.lungcan.2026.109382_b0105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2022.03.003","article-title":"DISTINCT study investigators, Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","volume":"166","author":"Edelman","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109382_b0110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archderm.134.2.185","article-title":"A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group","volume":"134","author":"Tyring","year":"1998","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.lungcan.2026.109382_b0115","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.40.3.245","article-title":"Acute adverse reactions attributed to allopurinol in hospitalised patients","volume":"40","author":"McInnes","year":"1981","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.lungcan.2026.109382_b0120","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"IMforte investigators, Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109382_b0125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cllc.2020.01.006","article-title":"Phase II trial of carfilzomib plus irinotecan in patients with small-cell lung cancer who have progressed on prior platinum-based chemotherapy","volume":"21","author":"Arnold","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109382_b0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Japan Clinical Oncology Group, Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109382_b0135","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","article-title":"Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124","volume":"27","author":"Lara","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109382_b0140","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1097\/01.JTO.0000283029.72261.4f","article-title":"E11-04: the role of irinotecan in the treatment of small cell lung cancer","volume":"2","author":"Hanna","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109382_b0145","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109382_b0150","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","article-title":"Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?","volume":"95","author":"Beutler","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2026.109382_b0155","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.23.02110","article-title":"RESILIENT Trial investigators, RESILIENT part 2: a randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer","volume":"42","author":"Spigel","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:26:40Z","timestamp":1776151600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"alternative-id":["S0169500226004435"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109382","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the safety and efficacy of chemotherapy in patients with relapsed small cell lung cancer combined with allopurinol and MycoPhenolate (CLAMP)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109382"}}